Small Business Informatics Tools for the Pangenome (R43 Clinical Trial Not Allowed)
ID: 357629Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357629

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-308.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Business Informatics Tools for the Pangenome (R43 Clinical Trial Not Allowed)" aimed at supporting the development of innovative informatics tools that enhance the use of the human pangenome reference. This initiative invites applications from eligible small business concerns (SBCs) to demonstrate the feasibility and commercial potential of such tools, particularly in the fields of clinical, population, and functional genomics. The funding, which can reach up to $400,000, is intended to foster the creation of tools that address significant gaps in genomic research and promote collaboration within the genomics community. Interested applicants must submit their proposals by March 3, 2025, and can find additional information and application guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-308-Full-Announcement.html
    PAR-25-308.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI), has released a Notice of Funding Opportunity (NOFO) aimed at fostering the development of small business informatics tools for the human pangenome. This initiative, under the Small Business Innovation Research (SBIR) grant program (R43), seeks applications from small business concerns (SBCs) that demonstrate the feasibility and commercial potential of such tools, particularly in clinical, population, and functional genomics. The goal is to enhance the adoption and utility of the human pangenome reference, which integrates diverse human genomes into a more representative resource. Key details include a funding budget up to $400,000 with a project duration of one year. Applications must focus on developing tools that facilitate the use of the pangenome, avoiding duplication of existing infrastructures. The NOFO emphasizes the need for innovative approaches that address significant gaps in genomic research and promote collaboration within the genomics community. Eligible applicants must be U.S.-based small businesses that meet specific criteria and demonstrate a commitment to ethical considerations in their research. The application process involves submission through Grants.gov, highlighting the importance of adhering to detailed guidelines to ensure compliance for review.
    Similar Opportunities
    Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)" aimed at advancing research in computational genomics, bioinformatics, and data visualization methodologies that enhance genomic science and its application to human health. This initiative seeks innovative projects that develop novel analytical tools and methodologies, with a budget limit of $275,000 for a two-year project period, focusing on scalable solutions applicable across various diseases and biological systems. The funding is particularly targeted at underrepresented entities in genomic research, including higher education institutions, nonprofits, and governmental bodies, reflecting NIH's commitment to fostering collaborative research in this critical field. Interested applicants should note that key submission dates begin on January 16, 2025, with a final expiration date of September 8, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research in computational genomics and data science. This initiative encourages applications that focus on developing novel analytical methodologies, tools, and software that can be broadly applied to enhance human health and disease understanding, with an emphasis on scalable systems for managing complex genomic data. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal colleges, with a maximum budget of $500,000 per year available for projects lasting up to five years. The application submission period opens on January 6, 2025, and closes on September 7, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Addressing Health Inequities in Clinical Diagnostics" under the Small Business Innovation Research (SBIR) program (R43/R44). This initiative invites Small Business Concerns (SBCs) to develop improved clinical diagnostics that address health disparities caused by existing clinical laboratory assays and point-of-care devices, particularly those that do not adequately consider diverse patient populations. The program aims to foster advancements that enhance health outcomes for historically underrepresented groups by encouraging applicants to identify specific disparities and propose innovative solutions. Applications will be accepted starting March 5, 2024, with a close date of January 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-158.html.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications, specifically requiring clinical trials. This funding opportunity is aimed at U.S. small businesses with the necessary research capabilities to contribute to the missions of the NIH and CDC, encouraging innovation and the commercial viability of health technologies. Eligible applicants can receive funding up to $306,872 for Phase I and $2,045,816 for Phase II, with a submission deadline of April 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html.
    ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the opportunity titled "ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)" to establish Expert Panels focused on the clinical relevance of genetic variants. The primary objective of this initiative is to develop a comprehensive knowledge base that enhances the interpretation of genes and genomic variants associated with high-priority diseases, utilizing established tools and resources from the Clinical Genomics Resource (ClinGen) and ClinVar. This funding is crucial for advancing genomic research and improving clinical outcomes through precision medicine, with a maximum award ceiling of $220,000 per year for a grant period of up to three years. Interested applicants must submit their proposals by May 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)" aimed at supporting small-scale research projects that enhance health equity through genomic research. The initiative seeks to develop innovative approaches and metrics to ensure the equitable application of genomics in improving health outcomes for U.S. populations, particularly focusing on historically underrepresented groups in biomedical research. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and state governments, with funding available up to $200,000 annually for a maximum of two years. Interested parties should submit their applications by July 8, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-018.html.